Net Revenues: $719.9 million for the full year. BAQSIMI Revenue: $185.4 million, up 12% year over year. Primatene Mist Revenue: $108.7 million, up 7% year over year. Iron Sucrose Revenue: $4.4 million ...

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

Shares of United Therapeutics climbed after the company said it planned to release a new soft mist inhaler to treat certain lung diseases next year. The stock rose 9%, to $515.94, midday Wednesday and ...

Amphastar Pharmaceuticals reported its fourth-quarter 2025 earnings, revealing a significant miss in both earnings per share (EPS) and revenue compared to analyst forecasts. The company’s EPS came in ...

Investing.com - Needham lowered its price target on Amphastar Pharmaceuticals (NASDAQ:AMPH) to $30 from $34 while maintaining a Buy rating following the company’s fourth-quarter results. Despite the ...

Changes in product revenues, net as compared to the fourth quarter of the prior year were primarily driven by: BAQSIMI ® sales increased primarily due to an increase in unit volumes, as a result of ...

Management explicitly guided to lower gross margins in 2026, attributing the pressure to "continued pricing pressure on glucagon, epinephrine, and phytonadione, which are high-margin products," and ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Amphastar Pharmaceuticals (AMPH) reported $183.11 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.8%. EPS of $0.73 for the same period compares to $0 ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...